Clinical trials
Systemic Lupus Erythematosus clinical trials
Below are recruiting systemic lupus erythematosus clinical trials, each written for real people, not researchers. We’re tracking 269 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06691152RecruitingPhase 1
CD19 UCAR T cells for severe lupus
This trial tests an experimental treatment called CD19 UCAR T cells for people with severe lupus that hasn't gotten better with standard medicines. It aims to see if these special immune cells can safely and effectively control the disease.
Hangzhou, ZhejiangAges 5 years+ - NCT06708845RecruitingPhase 1
Zamto-cel cell therapy for autoimmune diseases
This early-phase trial tests a new cell therapy called Zamto-cel for people with lupus (with or without kidney inflammation) or systemic sclerosis (hardening of the skin and internal organs). It is for those whose condition has not improved enough after standard treatments.
Milwaukee, WisconsinAges 18 years+ - NCT06710717RecruitingPhase 1
CD19 CAR T-cells for severe lupus
This early-phase trial tests whether a patient's own immune cells (T-cells) that are modified to target a protein called CD19 can help people with severe lupus that hasn't improved with other treatments. The goal is to reduce lupus activity and possibly achieve remission.
Bandar Tun Razak, Kuala LumpurAges 18–65 - NCT06737380RecruitingPhase 1
Stem Cell Therapy Study for Active Lupus
This study tests whether a special type of stem cell treatment (called UC-MSC) can help calm lupus when standard medicines aren't enough. It's for people with active lupus who have tried other non-steroid medications.
Charleston, South CarolinaAges 18–75 - NCT06789107RecruitingPhase 1
Blinatumomab for severe childhood lupus
This trial tests a drug called blinatumomab for children with active lupus that hasn't improved with standard treatments. It aims to see if this immunotherapy can help calm the immune system and reduce lupus activity.
Hangzhou, ZhejiangAges 5 years+ - NCT06794008RecruitingPhase 2
CAR-T cell therapy for hard-to-treat autoimmune diseases
This trial tests a new treatment using your own immune cells (called CAR-T cells) designed to target and attack cells that cause autoimmune diseases. It is for people with lupus, Sjögren's syndrome, inflammatory myopathy, scleroderma, Behcet's disease, ANCA-associated vasculitis, IgG4-related disease, antiphospholipid syndrome, or thrombotic thrombocytopenic purpura who have not improved with standard therapies.
Beijing, Beijing MunicipalityAges 18–65 - NCT06796569Recruiting
Blood test for inflammation in lupus patients
This study looks at a simple blood test (called the Systemic Immune Inflammatory Index) to see if it can help doctors understand how active lupus is in your body. It includes people with lupus, especially those with kidney involvement, to find better ways to track the disease.
Sohag, Sohag GovernorateAges 16 years+ - NCT06804057Recruiting
SLE drug safety registry for adults with lupus
This registry tracks the safety and effectiveness of lupus treatments over time. If you have SLE and are starting a new treatment or were recently diagnosed, joining helps doctors learn which medicines work best.
Waltham, MassachusettsAges 18 years+ - NCT06822881RecruitingPhase 1
Cell therapy for lupus and scleroderma
This trial tests a new cell therapy (CT1190B) for people with moderate to severe lupus or systemic sclerosis that has not responded to standard treatments. The therapy aims to calm the overactive immune system causing these autoimmune diseases.
Beijing, Beijing MunicipalityAges 18–60 - NCT06839976RecruitingPhase 1/Phase 2
CART19 cell therapy for lupus in young people
This trial tests whether a special type of immune cell, called CART19, can help young people with active lupus that hasn't gotten better with standard treatments. If you join, doctors will take some of your blood cells, modify them to attack lupus-causing cells, and then give them back to you.
Philadelphia, PennsylvaniaAges 12–29 - NCT06841042RecruitingPhase 1/Phase 2
Testing a new drug for active lupus
This study tests a new investigational drug called SCTB35 for people with active systemic lupus erythematosus (SLE or lupus). It aims to see if the drug is safe and effective in controlling lupus activity when added to your current stable lupus medications.
BeijingAges 18–75 - NCT06875960RecruitingPhase 4
Continuing deucravacitinib for people with lupus
This study lets people who have already finished a previous trial of deucravacitinib continue taking the medicine. It is for adults with lupus, including skin-only forms of the disease, to see if long-term treatment remains safe and helpful.
Farmington, ConnecticutAges 18–75 - NCT06881290RecruitingPhase 1
Vunakizumab for mild to moderate lupus
This trial tests a new drug called Vunakizumab for people with mild to moderate lupus that affects the skin or joints. It aims to see if adding this drug to your current treatment can help control symptoms better.
Beijing, Beijing MunicipalityAges 18–65 - NCT06902844Recruiting
Eque-cel for lupus that has not responded to other treatments
This trial tests a new cell therapy called eque-cel for people with lupus that has come back or is not controlled by standard treatments. It aims to see if this therapy can reduce lupus activity and improve symptoms.
Wuhan, HubeiAges 18 years+ - NCT06916806RecruitingPhase 1
Study of AZD5492 for lupus, myositis, or rheumatoid arthritis
This trial tests an investigational drug called AZD5492 for people with active lupus, inflammatory myositis, or rheumatoid arthritis who haven't responded well to other treatments. It aims to see if the drug is safe and how it works in the body.
Anniston, AlabamaAges 18–70 - NCT06920433RecruitingEarly Phase 1
Targeted cell therapy for tough lupus with kidney involvement
This early-phase trial tests a special immune cell therapy (UCAR T-cells) that targets two proteins (CD19 and BCMA) on the surface of lupus B cells. It is for people with difficult-to-treat lupus that affects the kidneys (lupus nephritis) who have not gotten better with standard treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT06921239Recruiting
HLA antibodies in lupus patients
This study looks for certain immune markers (HLA antibodies) in stored blood samples from people with lupus. It may help doctors understand how the immune system behaves in lupus.
AmiensAges 18 years+ - NCT06927219Recruiting
Lupus registry for patients and caregivers
This study creates a registry for people with lupus and their families. It helps researchers learn more about lupus and improve care. You or your child can join if you have a lupus diagnosis.
Washington D.C., District of ColumbiaAges Any age - NCT06941129RecruitingPhase 1
CAR T-cell therapy for resistant autoimmune diseases
This trial tests a new type of immune therapy called CAR T-cells that target two markers on your B cells (CD19 and BCMA). It is for people with certain autoimmune diseases that have not improved or have come back after standard treatments. The goal is to see if this therapy can help control the disease.
TianjinAges 18 years+ - NCT06943937RecruitingPhase 1
Cell therapy for hard-to-treat lupus
This trial tests a new type of cell therapy (YTS109 cells) for people with severe lupus that hasn't been controlled by standard treatments. The goal is to see if these cells can help calm the immune system and improve lupus symptoms.
Beijing, Beijing MunicipalityAges 18–65 - NCT06978647RecruitingPhase 1
YTS109 cell therapy for stubborn autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with certain autoimmune diseases like lupus that have not improved with standard treatments. It aims to see if this therapy can help control disease activity.
Beijing, Beijing MunicipalityAges 18–65 - NCT07000916Recruiting
Follow-up study for new arthritis in kids and young adults
This study follows children and young adults newly diagnosed with certain types of arthritis or related conditions to learn more about their health over time. It may help doctors better understand how these diseases progress and how treatments work.
BrusselsAges 2–50 - NCT07010835RecruitingPhase 1/Phase 2
Study of YK012 for moderate to severe lupus
This trial tests a new drug, YK012, for people with moderate to severe lupus. It aims to see if the drug can reduce disease activity and improve symptoms.
Beijing, Beijing MunicipalityAges 18–75 - NCT07011043RecruitingPhase 1
Study of budoprutug for lupus
This trial tests an investigational drug called budoprutug for people with active systemic lupus erythematosus (SLE) that has not improved after at least two previous treatments. The goal is to see if it can help control lupus symptoms.
Allen, TexasAges 18–65
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for systemic lupus erythematosus?
- Yes. Clin2 currently lists 269 recruiting systemic lupus erythematosus studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a systemic lupus erythematosus trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a systemic lupus erythematosus trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.